Samsung BioLogics readies W3tr IPO filing
Samsung Group’s drug manufacturing arm is set to file a draft prospectus with the Korea Exchange this week for an IPO that could raise up to W3tr ($2.7bn), according to a source with direct knowledge of the matter.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts